Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.2894
-0.0205 (-6.62%)
At close: Apr 23, 2026, 4:00 PM EDT
0.2720
-0.0174 (-6.01%)
After-hours: Apr 23, 2026, 7:57 PM EDT
Aditxt Revenue
In the year 2025, Aditxt had annual revenue of $3.20K, down -97.62%. Aditxt had revenue of $425.00 in the quarter ending December 31, 2025, a decrease of -86.61%.
Revenue (ttm)
$3.20K
Revenue Growth
-97.62%
P/S Ratio
81.93
Revenue / Employee
$123
Employees
26
Market Cap
261.75K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.20K | -130.79K | -97.62% |
| Dec 31, 2024 | 133.99K | -511.19K | -79.23% |
| Dec 31, 2023 | 645.18K | -288.54K | -30.90% |
| Dec 31, 2022 | 933.72K | 828.68K | 788.96% |
| Dec 31, 2021 | 105.03K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionADTX News
- 3 days ago - Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients - Business Wire
- 5 weeks ago - Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer - Business Wire
- 5 weeks ago - Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection - Business Wire
- 7 weeks ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026 - Business Wire
- 5 months ago - Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing - Business Wire
- 6 months ago - Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025 - Business Wire
- 6 months ago - Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market - Business Wire
- 6 months ago - Evofem Announces Voting Results from Special Meeting of Stockholders - PRNewsWire